2023 Fiscal Year Research-status Report
Nanomedicine-based Chemo-Immunotherapy for the Treatment of Pediatric Brain Cancer
| Project/Area Number |
22K12833
|
|---|
| Research Institution | Kawasaki Institute of Industrial Promotion Innovation Center of NanoMedicine |
|---|
Principal Investigator |
劉 学瑩 公益財団法人川崎市産業振興財団(ナノ医療イノベーションセンター), ナノ医療イノベーションセンター, 主任研究員 (30777470)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
喜納 宏昭 公益財団法人川崎市産業振興財団(ナノ医療イノベーションセンター), ナノ医療イノベーションセンター, 主幹研究員 (70283067)
Quader Sabina 公益財団法人川崎市産業振興財団(ナノ医療イノベーションセンター), ナノ医療イノベーションセンター, 副主幹研究員 (90749699)
|
|---|
| Project Period (FY) |
2022-04-01 – 2025-03-31
|
| Keywords | Nanomedicine / ICIs / medulloblastoma |
|---|
| Outline of Annual Research Achievements |
We have successfully developed and confirmed the effectiveness of a syngeneic mouse model for medulloblastoma, a type of brain tumor in our laboratory.
In our research, we have conducted extensive screenings of multiple anticancer drug-loaded nanomedicines against this model, leading to significant findings.
Furthermore, we have also conducted screenings of several immune checkpoint inhibitors (PD1, PDL1, CTLA-4, CD47, CD24, CD276) against the MB syngeneic model, resulting in important and promising research outcomes.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
A substantial amount of research-related data has been collected.
|
| Strategy for Future Research Activity |
Confirmation of synergistic or combination effect of anticancer drug-loaded nanomedicine and immune checkpoint inhibitors. Additionally, intellectual patent filing and dissemination of results through conference presentation and journal article publication.
|
| Causes of Carryover |
Due to other important commitments, it was not possible to attend the planned international conferences, which have been rescheduled for this fiscal year.
|
